{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:03:10Z","timestamp":1790492590514,"version":"4.1.0"},"reference-count":74,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The remarkable clinical activity of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) has transformed patient outcome. Consequently, allogeneic stem cell transplantation (allo-SCT) is no longer the only treatment modality with the ability to deliver long-term survival. In contrast to the central position it held in the treatment algorithm 20 years ago, allografting is now largely reserved for patients with either chronic-phase disease resistant to TKI therapy or advanced-phase disease. Over the same period, progress in transplant technology, principally the introduction of reduced intensity conditioning regimens coupled with increased donor availability, has extended transplant options in patients with CML whose outcome can be predicted to be poor if they are treated with TKIs alone. Consequently, transplantation is still a vitally important, potentially curative therapeutic modality in selected patients with either chronic- or advanced-phase CML. The major causes of transplant failure in patients allografted for CML are transplant toxicity and disease relapse. A greater understanding of the distinct contributions made by various factors such as patient fitness, patient-donor HLA disparity, conditioning regimen intensity, and transplant toxicity increasingly permits personalized transplant decision making. At the same time, advances in the design of conditioning regimens coupled with the use of adjunctive posttransplant cellular and pharmacologic therapies provide opportunities for reducing the risk of disease relapse. The role of SCT in the management of CML will grow in the future because of an increase in disease prevalence and because of continued improvements in transplant outcome.<\/jats:p>","DOI":"10.1182\/asheducation-2018.1.177","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T22:13:59Z","timestamp":1555452839000},"page":"177-184","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":37,"title":["We do still transplant CML, don\u2019t we?"],"prefix":"10.1182","volume":"2018","author":[{"given":"Charles F.","family":"Craddock","sequence":"first","affiliation":[{"name":"Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"14","key":"2019111520592169500_B1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111520592169500_B2","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111520592169500_B3","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1182\/blood-2014-10-567784","article-title":"The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century","volume":"125","author":"Barrett","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2019111520592169500_B4","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood-2010-08-301341","article-title":"Three decades of transplantation for chronic myeloid leukemia: what have we learned?","volume":"117","author":"Pavlu","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019111520592169500_B5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrclinonc.2015.193","article-title":"Allogeneic transplantation for CML in the TKI era: striking the right balance","volume":"13","author":"Innes","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"2019111520592169500_B6","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrclinonc.2012.150","article-title":"The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach","volume":"9","author":"Cornelissen","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"issue":"22","key":"2019111520592169500_B7","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111520592169500_B8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/sj.bmt.1705739","article-title":"Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant","volume":"40","author":"Vicente","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2019111520592169500_B9","first-page":"138","article-title":"Treatment of blastic transformation of chronic granulocytic leukemia by high dose cyclophosphamide, total body irradiation and infusion of cryopreserved autologous marrow","volume":"2","author":"Buckner","year":"1974","journal-title":"Exp Hematol"},{"issue":"7","key":"2019111520592169500_B10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM197902153000702","article-title":"Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin","volume":"300","author":"Fefer","year":"1979","journal-title":"N Engl J Med"},{"issue":"8299","key":"2019111520592169500_B11","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0140-6736(82)92736-2","article-title":"Marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia","volume":"2","author":"Goldman","year":"1982","journal-title":"Lancet"},{"issue":"8299","key":"2019111520592169500_B12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0140-6736(82)92735-0","article-title":"Treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation","volume":"2","author":"Clift","year":"1982","journal-title":"Lancet"},{"issue":"3","key":"2019111520592169500_B13","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1182\/blood-2004-07-2717","article-title":"Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy","volume":"105","author":"Barker","year":"2005","journal-title":"Blood"},{"issue":"10","key":"2019111520592169500_B14","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1602074","article-title":"Cord-blood transplantation in patients with minimal residual disease","volume":"375","author":"Milano","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111520592169500_B15","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/blood-2010-05-285304","article-title":"Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood","volume":"116","author":"Brunstein","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2019111520592169500_B16","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.bbmt.2017.04.001","article-title":"Transplantation of ex vivo expanded umbilical cord blood (NiCord) decreases early infection and hospitalization","volume":"23","author":"Anand","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl 2","key":"2019111520592169500_B17","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1038\/bmt.2015.92","article-title":"HLA-haploidentical blood or marrow transplantation with high-dose, post-transplantation cyclophosphamide","volume":"50","author":"Fuchs","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2019111520592169500_B18","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"issue":"6","key":"2019111520592169500_B19","doi-asserted-by":"crossref","first-page":"806","DOI":"10.7326\/0003-4819-108-6-806","article-title":"Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion","volume":"108","author":"Goldman","year":"1988","journal-title":"Ann Intern Med"},{"issue":"5","key":"2019111520592169500_B20","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"issue":"11","key":"2019111520592169500_B21","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","article-title":"Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects","volume":"97","author":"McSweeney","year":"2001","journal-title":"Blood"},{"issue":"20","key":"2019111520592169500_B22","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111520592169500_B23","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111520592169500_B24","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2019111520592169500_B25","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2019111520592169500_B26","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2019111520592169500_B27","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/blood-2013-07-513937","article-title":"Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors","volume":"123","author":"Kantarjian","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2019111520592169500_B28","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1182\/blood-2011-10-383000","article-title":"Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients","volume":"119","author":"Milojkovic","year":"2012","journal-title":"Blood"},{"issue":"15","key":"2019111520592169500_B29","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2019111520592169500_B30","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3324\/haematol.2009.012781","article-title":"Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia","volume":"95","author":"Milojkovic","year":"2010","journal-title":"Haematologica"},{"issue":"35","key":"2019111520592169500_B31","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1200\/JCO.2011.40.5217","article-title":"Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib","volume":"30","author":"Branford","year":"2012","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019111520592169500_B32","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1002\/cncr.30558","article-title":"Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation","volume":"123","author":"Nicolini","year":"2017","journal-title":"Cancer"},{"issue":"6","key":"2019111520592169500_B33","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1080\/10428194.2017.1379076","article-title":"Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting","volume":"59","author":"Boddu","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2019111520592169500_B34","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","article-title":"Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV","volume":"115","author":"Saussele","year":"2010","journal-title":"Blood"},{"issue":"14","key":"2019111520592169500_B35","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1056\/NEJM199804023381405","article-title":"Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia","volume":"338","author":"Hansen","year":"1998","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111520592169500_B36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1046\/j.1365-2141.2001.02519.x","article-title":"Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis","volume":"112","author":"Craddock","year":"2001","journal-title":"Br J Haematol"},{"issue":"13","key":"2019111520592169500_B37","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2007-06-097386","article-title":"High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation","volume":"110","author":"Lee","year":"2007","journal-title":"Blood"},{"issue":"16","key":"2019111520592169500_B38","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111520592169500_B39","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol"},{"issue":"11","key":"2019111520592169500_B40","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1182\/blood-2006-11-055186","article-title":"Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia","volume":"109","author":"Hehlmann","year":"2007","journal-title":"Blood"},{"issue":"11","key":"2019111520592169500_B41","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1182\/blood-2010-09-308510","article-title":"Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase","volume":"117","author":"Jiang","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2019111520592169500_B42","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood-2004-09-3544","article-title":"Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT","volume":"106","author":"Crawley","year":"2005","journal-title":"Blood"},{"issue":"17","key":"2019111520592169500_B43","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1182\/blood-2012-02-409763","article-title":"Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era","volume":"119","author":"Warlick","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2019111520592169500_B44","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.bbmt.2010.05.014","article-title":"Single-unit umbilical cord blood transplantation from unrelated donors in adult patients with chronic myelogenous leukemia","volume":"16","author":"Sanz","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2019111520592169500_B45","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.bbmt.2016.03.012","article-title":"Allogeneic Stem cell transplantation for patients with T315I BCR-ABL mutated chronic myeloid leukemia","volume":"22","author":"Xu","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2019111520592169500_B46","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3324\/haematol.2009.006999","article-title":"Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials","volume":"94","author":"Silver","year":"2009","journal-title":"Haematologica"},{"issue":"3","key":"2019111520592169500_B47","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.beha.2016.10.005","article-title":"Management of CML-blast crisis","volume":"29","author":"Hehlmann","year":"2016","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"2019111520592169500_B48","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","article-title":"How I treat CML blast crisis","volume":"120","author":"Hehlmann","year":"2012","journal-title":"Blood"},{"issue":"22","key":"2019111520592169500_B49","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/cncr.30864","article-title":"Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"issue":"3","key":"2019111520592169500_B50","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3324\/haematol.2011.057513","article-title":"Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation","volume":"97","author":"Milojkovic","year":"2012","journal-title":"Haematologica"},{"issue":"3","key":"2019111520592169500_B51","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/sj.leu.2404115","article-title":"High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia","volume":"20","author":"Rea","year":"2006","journal-title":"Leukemia"},{"issue":"3","key":"2019111520592169500_B52","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/cncr.28433","article-title":"HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia","volume":"120","author":"Strati","year":"2014","journal-title":"Cancer"},{"issue":"23","key":"2019111520592169500_B53","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1002\/cncr.30231","article-title":"Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis","volume":"122","author":"Sasaki","year":"2016","journal-title":"Cancer"},{"issue":"9134","key":"2019111520592169500_B54","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","article-title":"Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation","volume":"352","author":"Gratwohl","year":"1998","journal-title":"Lancet"},{"issue":"5","key":"2019111520592169500_B55","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2141.2004.04955.x","article-title":"Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants","volume":"125","author":"Passweg","year":"2004","journal-title":"Br J Haematol"},{"issue":"8","key":"2019111520592169500_B56","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"1","key":"2019111520592169500_B57","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/bmt.2014.215","article-title":"Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: A British Society of Blood and Marrow Transplantation study","volume":"50","author":"Nikolousis","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"25","key":"2019111520592169500_B58","doi-asserted-by":"crossref","first-page":"6963","DOI":"10.1182\/blood-2011-01-332007","article-title":"Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies","volume":"117","author":"Soiffer","year":"2011","journal-title":"Blood"},{"issue":"36","key":"2019111520592169500_B59","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2017.75.8177","article-title":"Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation","volume":"35","author":"Soiffer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111520592169500_B60","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.2009.26.7757","article-title":"Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase","volume":"28","author":"Goldman","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111520592169500_B61","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood.V95.1.67","article-title":"Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia","volume":"95","author":"Dazzi","year":"2000","journal-title":"Blood"},{"issue":"8","key":"2019111520592169500_B62","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1182\/blood.V96.8.2712","article-title":"Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"96","author":"Dazzi","year":"2000","journal-title":"Blood"},{"issue":"3","key":"2019111520592169500_B63","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/bmt.2009.177","article-title":"Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT","volume":"45","author":"Chalandon","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2019111520592169500_B64","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.bbmt.2014.09.012","article-title":"Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation","volume":"21","author":"Egan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019111520592169500_B65","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1182\/bloodadvances.2016000760","article-title":"Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia","volume":"1","author":"Quek","year":"2016","journal-title":"Blood Adv"},{"issue":"11","key":"2019111520592169500_B66","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/sj.bmt.1705167","article-title":"Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation","volume":"36","author":"Savani","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2019111520592169500_B67","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","article-title":"Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia","volume":"29","author":"Walter","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111520592169500_B68","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2008-02-141689","article-title":"Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia","volume":"112","author":"Lee","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2019111520592169500_B69","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.bbmt.2014.12.010","article-title":"Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation","volume":"21","author":"Copelan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"24","key":"2019111520592169500_B70","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2013-08-519009","article-title":"Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation","volume":"122","author":"Bredeson","year":"2013","journal-title":"Blood"},{"issue":"15","key":"2019111520592169500_B71","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S1470-2045(15)00200-4","article-title":"Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial","volume":"16","author":"Rambaldi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"12","key":"2019111520592169500_B72","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/sj.bmt.1704664","article-title":"Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease","volume":"34","author":"Weisser","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"24","key":"2019111520592169500_B73","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","article-title":"Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"23","author":"Schmid","year":"2005","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111520592169500_B74","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2007-04-082990","article-title":"Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia","volume":"110","author":"Olavarria","year":"2007","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/177\/1251367\/hem01823.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/177\/1251367\/hem01823.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T04:41:02Z","timestamp":1573879262000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2018\/1\/177\/277555\/We-do-still-transplant-CML-dont-we"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,11,30]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2018.1.177","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,30]]}}}